Yescarta, or axicabtagene ciloleucel, the second drug in a new class of chimeric antigen receptor T-cell therapy products developed to treat cancer, was approved by the FDA for patients with diffuse large B cell lymphoma. The treatment, originally developed by Kite Pharma, was acquired by Gilead Sciences in August, and a single dose is expected to cost $373,000.
FDA approves 2nd CAR-T therapy candidate -- Yescarta by Gilead
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.